hfpef tirzepatide ESC 2025: study supports use of semaglutide, in cardiometabolic patients Effectiveness of tirzepatide in patients

The pill or injection is preferred

Favorable 0% Mixed 0% Unfavorable overall 100% Most reported benefits Benefits users selected when logging a favorable or mixed check-in

Jastreboff, MD, PhD Director, Weight Management & Obesity Prevention Yale School of Medicine, New Haven, Connecticut Professor Ania Jastreboff has been a principal investigator for pivotal GLP3 clinical trials, including the landmark phase 2 obesity study published in the New England Journal of Medicine

More on that in the reviews section

A randomized clinical trial of once-weekly exenatide for alcohol use disorder published in JAMA Psychiatry (2022) did not meet its primary endpoint of reducing heavy drinking days in the overall study population